Cellceutix presenting at TAP with the BIG DOGS!
Post# of 72447
Posted On: 09/30/2013 12:33:14 PM
Cellceutix presenting at TAP with the BIG DOGS !
Therapeutic Area Partnerships (TAP)
Grow the Value of your Assets through Financing, M & A and Strategic Partnerships
A meeting for the sharpest minds in biopharma. Since its launch eight years ago, Therapeutic Area Partnerships (TAP) has come to be regarded as the industry's premier biopharmaceutical partnering event. A uniquely efficient gathering, TAP brings together decision-makers to assess the most promising drug programs available for partnering in:
Oncology • Cardiovascular/Metabolic Diseases • Neuroscience • Infectious Diseases • Anti-Inflammatory/Autoimmune Diseases • Advanced Therapies (Cellular and Gene Therapies, Rare Diseases and other high value and niche areas)
Attendees have the opportunity to hear from and meet some of the industry's most talented biotechnology entrepreneurs and pharmaceutical leaders. Casual gatherings and one-on-one partnering meetings bring together business development decision makers from large pharmaceutical firms and executive leadership from innovative biotechnology firms to make this one of the industry's most productive events. Learn more about the many benefits TAP has to off or View the Top 10 Reasons to Attend TAP.
Top Projects to Watch
The Top Projects to Watch are chosen to present in each therapeutic area, and are hand-picked by a panel of independent experts who screen hundreds of compounds and weigh their potential as future products. Many presenting companies in previous years have gone on to establish major partnerships - Trius, Optimer, QRxPharma, Pearl Therapeutics, Vectura, AVEO, Trophos, and BiPar – just to name a few.
The criteria were:
Large market, large unmet need, with increasing opportunity
History of the molecule and drug
Strong science
Strong company
Diversity of indications
Potential for new opportunities beyond the initial indications
Multi-level partnering opportunities, i.e., biotech to biotech as well as pharma to biotech
All companies will present on November 19 and will be available for 1:1 partnering meetings during November 19-20.
http://www.elsevierbi.com/mkt/Conf/TAP2013/TAP2013
All companies will present on November 19 and will be available for 1:1 partnering meetings during November 19-20.
Cellceutix is under the Infectious Diseases tab
http://www.elsevierbi.com/mkt/Conf/TAP2013/PresentingCos
Therapeutic Area Partnerships (TAP)
Grow the Value of your Assets through Financing, M & A and Strategic Partnerships
A meeting for the sharpest minds in biopharma. Since its launch eight years ago, Therapeutic Area Partnerships (TAP) has come to be regarded as the industry's premier biopharmaceutical partnering event. A uniquely efficient gathering, TAP brings together decision-makers to assess the most promising drug programs available for partnering in:
Oncology • Cardiovascular/Metabolic Diseases • Neuroscience • Infectious Diseases • Anti-Inflammatory/Autoimmune Diseases • Advanced Therapies (Cellular and Gene Therapies, Rare Diseases and other high value and niche areas)
Attendees have the opportunity to hear from and meet some of the industry's most talented biotechnology entrepreneurs and pharmaceutical leaders. Casual gatherings and one-on-one partnering meetings bring together business development decision makers from large pharmaceutical firms and executive leadership from innovative biotechnology firms to make this one of the industry's most productive events. Learn more about the many benefits TAP has to off or View the Top 10 Reasons to Attend TAP.
Top Projects to Watch
The Top Projects to Watch are chosen to present in each therapeutic area, and are hand-picked by a panel of independent experts who screen hundreds of compounds and weigh their potential as future products. Many presenting companies in previous years have gone on to establish major partnerships - Trius, Optimer, QRxPharma, Pearl Therapeutics, Vectura, AVEO, Trophos, and BiPar – just to name a few.
The criteria were:
Large market, large unmet need, with increasing opportunity
History of the molecule and drug
Strong science
Strong company
Diversity of indications
Potential for new opportunities beyond the initial indications
Multi-level partnering opportunities, i.e., biotech to biotech as well as pharma to biotech
All companies will present on November 19 and will be available for 1:1 partnering meetings during November 19-20.
http://www.elsevierbi.com/mkt/Conf/TAP2013/TAP2013
All companies will present on November 19 and will be available for 1:1 partnering meetings during November 19-20.
Cellceutix is under the Infectious Diseases tab
http://www.elsevierbi.com/mkt/Conf/TAP2013/PresentingCos
(0)
(0)